BERRY GENOMICS CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.36 CNY | +0.14% |
|
+6.20% | -36.11% |
| Feb. 05 | Berry Genomics to Sell Fujian Industrial Park Assets to New JV | MT |
| 2023 | Berry Genomics Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 1.42B 196M | Sales 2022 | 1.37B 189M | Capitalization | 4.03B 557M |
|---|---|---|---|---|---|
| Net income 2021 | -111M -15.32M | Net income 2022 | -255M -35.19M | EV / Sales 2021 | 4.77 x |
| Net cash position 2021 | 22.7M 3.13M | Net Debt 2022 | 10.11M 1.39M | EV / Sales 2022 | 2.96 x |
| P/E ratio 2021 |
-62.6
x | P/E ratio 2022 |
-13.9
x | Employees | 1,438 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.19% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.14% | ||
| 1 week | +6.20% | ||
| Current month | -22.12% | ||
| 1 month | -36.28% | ||
| 3 months | -23.81% | ||
| 6 months | -20.43% | ||
| Current year | -36.11% |
1 week
6.88
7.78
1 month
6.7211.40
Current year
5.4013.16
1 year
5.4016.48
3 years
5.4036.37
5 years
5.4098.00
10 years
5.4098.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yang Gao
CEO | Chief Executive Officer | 44 | 97-04-13 |
Dong Wang
DFI | Director of Finance/CFO | 51 | 17-07-19 |
Hong Yan Chen
ADM | Chief Administrative Officer | 38 | 20-08-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang Gao
CEO | Chief Executive Officer | 44 | 97-04-13 |
| 48 | - | ||
Dong Wang
DFI | Director of Finance/CFO | 51 | 17-07-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 7.36 | +0.14% | 9 249 201 |
| 24-04-23 | 7.35 | +4.70% | 11,695,900 |
| 24-04-22 | 7.02 | -2.09% | 8,166,400 |
| 24-04-19 | 7.17 | -3.63% | 11,501,500 |
| 24-04-18 | 7.44 | +1.22% | 15,971,950 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Berry Genomics Co Ltd is a company mainly engaged in medical testing related services. The Company's business is comprised of basic scientific research services, medical testing services, testing reagent sales and testing equipment sales. The basic scientific research services business provides the clients with multiple sequencing platforms for testing projects, such as transcriptome sequencing, human whole exome sequencing and whole genome sequencing. The medical testing services business include tumor genetic testing services, genetic disease genetic testing services and reproductive health testing services. The Company sells a range of reagents and equipment, including NextSeq CN500 gene sequencer and general reagents for sequencing reactions.
Calendar
2024-04-24
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.11% | 359M | |
| -16.65% | 8.36B | |
| +40.72% | 3.6B | |
| -32.00% | 2.87B | |
| -7.71% | 2.47B | |
| -9.65% | 2.24B | |
| -13.60% | 1.81B | |
| -19.62% | 1.56B | |
| -40.57% | 1.23B | |
| +9.70% | 1.13B |
- Stock Market
- Equities
- 000710 Stock
